Anti-thymocyte globulins capable of binding to T and B cells reduce graft-vs-host disease without increasing relapse

Bone Marrow Transplantation

Volumn 48, Issue 1, 2013, Pages 105-114

  Hoegh Petersen, M ^a,d   Amin, M A ^a   Liu, Y ^a   Ugarte Torres, A ^a,b   Williamson, T S ^a   Podgorny, P J ^a   Russell, J A ^b   Grigg, A ^c   Ritchie, D ^c   Storek, J ^a,b  

^a UNIVERSITY OF CALGARY   (Canada)

^b ALBERTA HEALTH SERVICES   (Canada)

^c ROYAL MELBOURNE HOSPITAL   (Australia)

^d UNIVERSITY OF CALGARY   (Canada)

Author keywords

Anti thymocyte globulin; GVHD; Hematopoietic cell transplantation

Indexed keywords

THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; AGED; ANTIBODY SPECIFICITY; ANTIGEN BINDING; ARTICLE; B LYMPHOCYTE; BACTERIAL INFECTION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHRONIC GRAFT VERSUS HOST DISEASE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MYCOSIS; MYELOABLATIVE CONDITIONING; NATURAL KILLER T CELL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; RELAPSE; RISK ASSESSMENT; RISK REDUCTION; T LYMPHOCYTE SUBPOPULATION; VIRUS INFECTION;

ADULT; AGED; ALBERTA; ANEMIA, APLASTIC; ANTILYMPHOCYTE SERUM; B-LYMPHOCYTES; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; LEUKEMIA; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; OPPORTUNISTIC INFECTIONS; RECURRENCE; SEVERITY OF ILLNESS INDEX; T-LYMPHOCYTES; VIRUS DISEASES; YOUNG ADULT;

EID: 84872165385     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2012.99     Document Type: Article

References (43)

1. Bacigalupo A, Lamparelli T, Bruzzi P, Guidi S, Alessandrino PE, di Bartolomeo P et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood 2001; 98: 2942-2947.
2. Remberger M, Sundberg B. Rabbit-immunoglobulin G levels in patients receiving thymoglobulin as part of conditioning before unrelated donor stem cell transplantation. Haematologica 2005; 90: 931-938. (Pubitemid 41020296)
3. Remberger M, Sundberg B. Low serum levels of total rabbit-IgG is associated with acute graft-versus-host disease after unrelated donor hematopoietic stem cell transplantation: results from a prospective study. Biol Blood Marrow Transplant 2009; 15: 996-999.
4. Kim HJ, Min WS, Cho BS, Eom KS, Kim YJ, Min CK et al. Successful prevention of acute graft-versus-host disease using low-dose antithymocyte globulin after mismatched, unrelated, hematopoietic stem cell transplantation for acute myelogenous leukemia. Biol Blood Marrow Transplant 2009; 15: 704-717.
5. Bacigalupo A, Lamparelli T, Barisione G, Bruzzi P, Guidi S, Alessandrino PE et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biol Blood Marrow Transplant 2006; 12: 560-565. (Pubitemid 43956361)
6. Bacigalupo A, Lamparelli T, Milone G, Sormani MP, Ciceri F, Peccatori J et al. Preemptive treatment of acute GVHD: a randomized multicenter trial of rabbit antithymocyte globulin, given on day+7 after alternative donor transplants. Bone Marrow Transplant 2010; 45: 385-391.
7. Russell JA, Turner AR, Larratt L, Chaudhry A, Morris D, Brown C et al. Adult recipients of matched related donor blood cell transplants given myeloablative regimens including pretransplant antithymocyte globulin have lower mortality related to graft-versus-host disease: a matched pair analysis. Biol Blood Marrow Transplant 2007; 13: 299-306.
8. Bredeson CN, Zhang MJ, Agovi MA, Bacigalupo A, Bahlis NJ, Ballen K et al. Outcomes following HSCT using fludarabine, busulfan, and thymoglobulin: a matched comparison to allogeneic transplants conditioned with busulfan and cyclophosphamide. Biol Blood Marrow Transplant 2008; 14: 993-1003.
9. Finke J, Bethge WA, Schmoor C, Ottinger HD, Stelljes M, Zander AR et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol 2009; 10: 855-864.
10. Socie G, Schmoor C, Bethge WA, Ottinger HD, Stelljes M, Zander AR et al. Chronic graft-versus-host disease: long-term results from a randomized trial on graftversus-host disease prophylaxis with or without anti-T-cell globulin ATGFresenius. Blood 2011; 117: 6375-6382.
11. Mohty M, Labopin M, Balere ML, Socie G, Milpied N, Tabrizi R et al. Antithymocyte globulins and chronic graft-vs-host disease after myeloablative allogeneic stem cell transplantation from HLA-matched unrelated donors: a report from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. Leukemia 2010; 24: 1867-1874.
12. Podgorny PJ, Ugarte-Torres A, Liu Y, Williamson TS, Russell JA, Storek J. High rabbit-antihuman thymocyte globulin levels are associated with low likelihood of graft-vs-host disease and high likelihood of posttransplant lymphoproliferative disorder. Biol Blood Marrow Transplant 2010; 16: 915-926.
13. Mohty M. Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond. Leukemia 2007; 21: 1387-1394. (Pubitemid 46965279)
14. Socie G, Blazar BR. Acute graft-versus-host disease: from the bench to the bedside. Blood 2009; 114: 4327-4336.
15. Kohrt HE, Pillai AB, Lowsky R, Strober SNKT. cells, Treg, and their interactions in bone marrow transplantation. Eur J Immunol 2010; 40: 1862-1869.
16. Soiffer RJ, Lerademacher J, Ho V, Kan F, Artz A, Champlin RE et al. Impact of immune modulation with anti-T-cell antibodies on the outcome of reducedintensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Blood 2011; 117: 6963-6970.
17. Coghill JM, Carlson MJ, Panoskaltsis-Mortari A, West ML, Burgents JE, Blazar BR et al. Separation of graft-versus-host disease from graft-versus-leukemia responses by targeting CC-chemokine receptor 7 on donor T cells. Blood 2010; 115: 4914-4922.
18. Moncrieffe H, Coles M, Stockinger B. The influence of CD4 T-cell subsets on control of CD4 T-cell-mediated graft-versus-host disease. Immunology 2008; 125: 459-468.
19. Beilhack A, Schulz S, Baker J, Beilhack GF, Wieland CB, Herman EI et al. In vivo analyses of early events in acute graft-versus-host disease reveal sequential infiltration of T-cell subsets. Blood 2005; 106: 1113-1122. (Pubitemid 41076462)
20. Yakoub-Agha I, Saule P, Depil S, Micol JB, Grutzmacher C, Boulanger-Villard F et al. A high proportion of donor CD4+ T cells expressing the lymph node-homing chemokine receptor CCR7 increases incidence and severity of acute graft-versushost disease in patients undergoing allogeneic stem cell transplantation for hematological malignancy. Leukemia 2006; 20: 1557-1565. (Pubitemid 44264099)
21. Zeng D, Lewis D, Dejbakhsh-Jones S, Lan F, Garcia-Ojeda M, Sibley R et al. Bone marrow NK1.1(-) and NK1.1(+) T cells reciprocally regulate acute graft versus host disease. J Exp Med 1999; 189: 1073-1081. (Pubitemid 29169824)
22. Pillai AB, George TI, Dutt S, Strober S. Host natural killer T cells induce an interleukin-4-dependent expansion of donor CD4+CD25+Foxp3+ T regulatory cells that protects against graft-versus-host disease. Blood 2009; 113: 4458-4467.
23. Di Ianni M, Falzetti F, Carotti A, Terenzi A, Castellino F, Bonifacio E et al. Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood 2011; 117: 3921-3928.
24. Magenau JM, Qin X, Tawara I, Rogers CE, Kitko C, Schlough M et al. Frequency of CD4(+)CD25(hi)FOXP3(+) regulatory T cells has diagnostic and prognostic value as a biomarker for acute graft-versus-host-disease. Biol Blood Marrow Transplant 2010; 16: 907-914.
25. Brunstein CG, Miller JS, Cao Q, McKenna DH, Hippen KL, Curtsinger J et al. Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood 2011; 117: 1061-1070.
26. Lord JD, Hackman RC, Gooley TA, Wood BL, Moklebust AC, Hockenbery DM et al. Blood and gastric FOXP3+ T cells are not decreased in human gastric graftversus-host disease. Biol Blood Marrow Transplant 2011; 17: 486-496.
27. Clark FJ, Gregg R, Piper K, Dunnion D, Freeman L, Griffiths M et al. Chronic graftversus-host disease is associated with increased numbers of peripheral blood CD4+CD25 high regulatory T cells. Blood 2004; 103: 2410-2416. (Pubitemid 38326268)
28. Lapalombella R, Yu B, Triantafillou G, Liu Q, Butchar JP, Lozanski G et al. Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibodydependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells. Blood 2008; 112: 5180-5189.
29. Sanchez J, Casano J, Alvarez MA, Roman-Gomez J, Martin C, Martinez F et al. Kinetic of regulatory CD25high and activated CD134+ (OX40) T lymphocytes during acute and chronic graft-versus-host disease after allogeneic bone marrow transplantation. Br J Haematol 2004; 126: 697-703. (Pubitemid 39221306)
30. Lopez M, Clarkson MR, Albin M, Sayegh MH, Najafian N. A novel mechanism of action for anti-thymocyte globulin: induction of CD4+CD25+Foxp3+ regulatory T cells. J Am Soc Nephrol 2006; 17: 2844-2853. (Pubitemid 44484674)
31. Feng X, Kajigaya S, Solomou EE, Keyvanfar K, Xu X, Raghavachari N et al. Rabbit ATG but not horse ATG promotes expansion of functional CD4+ CD25highFOXP3+ regulatory T cells in vitro. Blood 2008; 111: 3675-3683.
32. Shimabukuro-Vornhagen A, Hallek MJ, Storb RF, von Bergwelt-Baildon MS. The role of B cells in the pathogenesis of graft-versus-host disease. Blood 2009; 114: 4919-4927.
33. Ratanatharathorn V, Logan B, Wang D, Horowitz M, Uberti JP, Ringden O et al. Prior rituximab correlates with less acute graft-versus-host disease and better survival in B-cell lymphoma patients who received allogeneic peripheral blood stem cell transplantation. Br J Haematol 2009; 145: 816-824.
34. Christopeit M, Schutte V, Theurich S, Weber T, Grothe W, Behre G. Rituximab reduces the incidence of acute graft-versus-host disease. Blood 2009; 113: 3130-3131.
35. Rowe V, Banovic T, MacDonald KP, Kuns R, Don AL, Morris ES et al. Host B cells produce IL-10 following TBI and attenuate acute GVHD after allogeneic bone marrow transplantation. Blood 2006; 108: 2485-2492. (Pubitemid 44497537)
36. Pavletic SZ, Vogelsang GB. Chronic graft-vs-host disease: clinical manifestations and therapy. In: Appelbaum FR, Forman SJ, Negrin RS, Blume KG (eds) Thomas' Hematopoietic Cell Transplantation. Blackwell Publishing: West Sussex, UK, 2009, pp 1304-1324.
37. Grullich C, Ziegler C, Finke J. Rabbit anti T-lymphocyte globulin induces apoptosis in peripheral blood mononuclear cell compartments and leukemia cells, while hematopoetic stem cells are apoptosis resistant. Biol Blood Marrow Transplant 2009; 15: 173-182.
38. Teng MW, Ritchie DS, Neeson P, Smyth MJ. Biology and clinical observations of regulatory T cells in cancer immunology. Curr Top Microbiol Immunol 344: 61-95.
39. Nishikawa H, Sakaguchi S. Regulatory T cells in tumor immunity. Int J Cancer 127: 759-767.
40. Styczynski J, Einsele H, Gil L, Ljungman P. Outcome of treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases. Transpl Infect Dis 2009; 11: 383-392.
41. Reddy N, Rezvani K, Barrett AJ, Savani BN. Strategies to prevent EBV reactivation adn posttransplant lymphoproliferative disorders (PTLD) after allogeneic stem cell transplantation in high-risk patients. Biol Blood Marrow Transplant 2011; 17: 591-597.
42. Coutinho R, Clear AJ, Owen DA, Greaves P, Hallam SL, Wilson A et al. Exploring the microenvironment of diffuse large B cell lymphoma in a tissue microarray - predicting survival with a score that incorporates macrophages, cytotoxic and regulatory T cells. In: American Society of Hematology Annual Meeting, San Diego, CA, Blood 2011; 118: 434-435.
43. Ladoire S, Martin F, Ghiringhelli F. Prognostic role of FOXP3+ regulatory T cells infiltrating human carcinomas: the paradox of colorectal cancer. Cancer Immunol Immunother 2011; 60: 909-918.